Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Streptococcus pyogenes

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    8 result(s) found for: Streptococcus pyogenes. Displaying page 1 of 1.
    EudraCT Number: 2020-002219-24 Sponsor Protocol Number: IMPET-001 Start Date*: 2020-08-17
    Sponsor Name:Basic Pharma Technologies
    Full Title: A Randomized, Double-Blind, Parallel Group, Equivalence, Multicenter Phase III Trial to Compare the Efficacy and Safety of Fusidic Acid Hydrophilic Cream 20 mg/g and Fucidin® Cream in the Treatment...
    Medical condition: Impetigo contagiosa
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10021531 Impetigo PT
    20.0 10021881 - Infections and infestations 10041923 Staphylococcal impetigo PT
    20.0 10021881 - Infections and infestations 10042178 Streptococcal impetigo PT
    20.0 10021881 - Infections and infestations 10021535 Impetigo NOS LLT
    20.1 10021881 - Infections and infestations 10041939 Staphylococcus aureus impetigo LLT
    20.0 10021881 - Infections and infestations 10042200 Streptococcus pyogenes impetigo LLT
    20.1 10021881 - Infections and infestations 10021533 Impetigo contagious LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-004631-39 Sponsor Protocol Number: EFC6134,HMR3647B/3006 Start Date*: 2015-03-17
    Sponsor Name:Sanofi-aventis
    Full Title: Multinational, randomized, double blind, comparative study to evaluate the efficacy and safety of telithromycin, 800 mg once daily for 5 days, versus penicillin V, 500 mg three times daily for 10 d...
    Medical condition: Tonsillitis Pharyngitis
    Disease: Version SOC Term Classification Code Term Level
    17.1 10021881 - Infections and infestations 10049140 Pharyngotonsillitis PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2014-004630-26 Sponsor Protocol Number: EFC6133,HMR3647B/3004 Start Date*: 2015-03-17
    Sponsor Name:Sanofi-aventis
    Full Title: Multinational, Randomized, Double-Blind, Double Dummy, Comparative Study to Evaluate the Efficacy and Safety of 5 Days Telithromycin 25mg/kg od Versus 10 Days Penicillin V 13.3 mg/kg Tid in Childre...
    Medical condition: Tonsillitis Pharyngitis
    Disease: Version SOC Term Classification Code Term Level
    17.1 10021881 - Infections and infestations 10049140 Pharyngotonsillitis PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2011-003402-25 Sponsor Protocol Number: OCT-UKE-2011 Start Date*: 2011-12-13
    Sponsor Name:Schülke & Mayr GmbH
    Full Title: Randomized, Double-blind, Single-center, Placebo-controlled Study to evaluate the Efficacy of octenisept® in Patients with Chronic Wounds.
    Medical condition: Chronic leg ulcers
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004858 10068310 Leg ulcer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-002001-30 Sponsor Protocol Number: IMUP Start Date*: 2011-12-09
    Sponsor Name:INFECTOPHARM Arzneimittel und Consilium GmbH
    Full Title: Multicenter, prospective, double-blind, two-armed phase III study for efficacy and safety of the topic impetigo therapy of two 2 % mupirocin ointments
    Medical condition: Impetigo
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2014-004002-15 Sponsor Protocol Number: KETOP_L_03102 Start Date*: 2014-12-19
    Sponsor Name:Sanofi
    Full Title: Local, Phase IV, Multicenter, Double-blind, Randomized, Parallel, With Two Treatment Arms, Placebo-controlled Study to Evaluate the Reduction of Inflammatory Symptoms in the Treatment of Bacterial ...
    Medical condition: Pharyngotonsillitis
    Disease: Version SOC Term Classification Code Term Level
    17.1 10021881 - Infections and infestations 10049140 Pharyngotonsillitis PT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2022-000886-42 Sponsor Protocol Number: BV-2020/08 Start Date*: 2022-09-06
    Sponsor Name:OM Pharma SA
    Full Title: A Randomised, Placebo-Controlled, 3-Arm, Double-Blind, Multicentre, Phase 4 Study to Assess the Efficacy of OM-85 (Broncho Vaxom) Short- and Long-Term Treatment vs. Placebo in the Prevention of Res...
    Medical condition: Respiratory Tract Infections with Wheezing Lower Respiratory Illness
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10024970 Respiratory tract infections HLGT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: HU (Trial now transitioned) PL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-003179-33 Sponsor Protocol Number: BV-2021/06 Start Date*: 2021-11-29
    Sponsor Name:OM Pharma SA
    Full Title: A Randomised, Double-Blind, Placebo-controlled, 32-week, Phase IIa trial to investigate the efficacy of OM-85 versus matched placebo in reducing disease severity in children aged 3 to 24 months wit...
    Medical condition: Atopic Dermatitis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10012438 Dermatitis atopic PT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) NL (Prematurely Ended) PL (Prematurely Ended) FR (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 31 09:39:42 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA